1 SLC39A8.p.(Ala391Thr) is associated with poorer cognitive ability: a

2 cross-sectional study of schizophrenia and the general UK population

3 Authors

- 4 Sophie E Smart^{1*}
- 5 Sophie E. Legge¹
- 6 Eilidh Fenner¹
- 7 Antonio F. Pardiñas¹
- 8 Grace Woolway¹
- 9 Amy J. Lynham¹
- 10 Valentina Escott-Price¹
- 11 Jeremy Hall²
- 12 Lawrence Wilkinson¹
- 13 Peter Holmans¹
- 14 Michael C. O'Donovan¹
- 15 Michael J. Owen^{1,2}
- 16 James T.R. Walters¹
- 17
- 18 ¹ Centre for Neuropsychiatric Genetics and Genomics, Division of Psychological Medicine
- 19 and Clinical Neurosciences, Cardiff University, Cardiff, UK
- 20 ² Neuroscience and Mental Health Innovation Institute, Division of Psychological Medicine
- 21 and Clinical Neurosciences, Cardiff University, Cardiff, UK
- 22 *Corresponding author: SmartS1@cardiff.ac.uk

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

23 Abstract

24 The missense SNP NC_000004.12:g.102267552C>T (SLC39A8.p.(Ala391Thr), rs13107325) 25 in SLC39A8, which encodes a zinc transporter, has been linked to schizophrenia and is the 26 likely causal variant for one of the genome-wide association loci associated with the disorder. 27 We tested whether the schizophrenia-risk allele at p.(Ala391Thr) was associated with 28 29 schizophrenia-related phenotypes, including positive, negative, and disorganised symptoms, 30 cognitive ability, educational attainment, and age of psychosis onset, within three 31 schizophrenia cohorts (combined N=1,232) and, with equivalent phenotypes, in a sample of 32 population controls (UK Biobank, N=355,069). We used regression analyses controlling for 33 age, sex, and population stratification. 34 35 Within the schizophrenia cohorts, after correction for multiple testing, p.(Ala391Thr) was not 36 significantly associated with any schizophrenia-related phenotypes. In the unaffected 37 participants from the UK Biobank, the schizophrenia-risk allele at p.(Ala391Thr) was 38 associated with significantly poorer cognitive ability and fluid intelligence, a lower 39 probability of obtaining GCSEs or a degree-level qualification, and fewer years in education. 40 There was no association between p.(Ala391Thr) and self-reported psychotic experiences in 41 this cohort. 42 43 The schizophrenia-risk allele was associated with poorer cognitive ability, but not psychotic 44 experiences, in a volunteer sample drawn from of the general population. To determine 45 whether p.(Ala391Thr) is associated with cognitive phenotypes in people with schizophrenia, 46 and to understand the role of p.(Ala391Thr) in the aetiology of cognitive impairment in

47 schizophrenia, larger independent samples are required.

48

49 Keywords: ZIP8, rs13107325, metal ion transporters, psychosis, rare variants

50 Introduction

| 51 | |
|----|---|
| 52 | The gene SLC39A8 encodes metal cation symporter ZIP8, which enables the movement of at |
| 53 | least five trace elements (manganese, zinc, iron, selenium, and cobalt) from outside the cell |
| 54 | into the cytosol. SLC39 genes are highly conserved and are critical for fundamental life |
| 55 | processes throughout the lifespan. SLC39A8 contains a missense single nucleotide |
| 56 | polymorphism (SNP), NC_000004.12:g.102267552C>T (SLC39A8.p.(Ala391Thr), |
| 57 | rs13107325), in which alternative alleles encode alanine (Ala; C allele) or threonine (Thr; T |
| 58 | allele) on chromosome 4 (1). In vitro, the minor allele (T) leads to reduced uptake of |
| 59 | manganese and cadmium (2), the latter a toxic environmental pollutant, and decreased |
| 60 | synaptic uptake of zinc (3). |
| 61 | |
| 62 | p.(Ala391Thr) is associated with an increased risk of schizophrenia, a heterogeneous disorder |
| 63 | whose presentation includes delusions, hallucinations, behavioural disturbance, social |
| 64 | withdrawal, and cognitive impairment. In the most recent genome-wide association study |
| 65 | (GWAS), of 69,369 schizophrenia cases and 236,642 controls, the minor allele was |
| 66 | associated with increased the risk of schizophrenia (odds ratio=1.17, P= 2.9×10^{-21}) (4). |
| 67 | Furthermore, fine-mapping suggested that p.(Ala391Thr) was likely to be the causal variant |
| 68 | underpinning the association with the genomic region containing SLC39A8, the SNP having a |
| 69 | posterior probability of being causally associated with schizophrenia of 99.20%. Only nine |
| 70 | out of 255 loci were fine-mapped to one causal variant (4), only two of these were missense |
| 71 | variants, and only p.(Ala391Thr) had a Combined Annotation-Dependent Depletion (CADD) |
| 72 | score of 22 making it one of the 1% most deleterious variants in the genome. |
| 73 | |

| 74 | In non-psychiatric populations, p.(Ala391Thr) has not been associated with reported |
|----|--|
| 75 | psychotic experiences ($Z = 0.99$, $P = 0.889$) (5), but the schizophrenia risk allele has been |
| 76 | associated with lower intelligence (Z = -9.49, P = $2.23E-21$) (6), fewer years in education |
| 77 | (Beta = -0.02, $P = 1.08E-13$) (7), and, using a GWAS-by-subtraction design, with the |
| 78 | cognitive aspect of educational attainment (NonCog, $Z = 2.78$, $P = 0.005$; Cog, $Z = -9.87$; $P = 0.005$; Cog, $Z = -9.87$; $P = 0.005$; Cog, $Z = -9.87$; $P = 0.005$; Cog, $Z = -9.87$; $P = 0.005$; Cog, $Z = -9.87$; $P = 0.005$; Cog, $Z = -9.87$; $P = 0.005$; Cog, $Z = -9.87$; $P = 0.005$; Cog, $Z = -9.87$; $P = 0.005$; Cog, $Z = -9.87$; $P = 0.005$; Cog, $Z = -9.87$; $P = 0.005$; Cog, $Z = -9.87$; $P = 0.005$; Cog, $Z = -9.87$; $P = 0.005$; Cog, $Z = -9.87$; $P = 0.005$; Cog, $Z = -9.87$; $P = 0.005$; Cog, $Z = -9.87$ |
| 79 | 5.59E-23) (8). To date, no studies have examined the relationship between p.(Ala391Thr) and |
| 80 | the clinical presentation or cognitive ability of people with schizophrenia. |
| 81 | |

81

82 Our primary aim was to test whether schizophrenia-risk alleles at p.(Ala391Thr) are

83 associated with phenotypes that capture the clinical presentation of schizophrenia. We

84 hypothesised that the schizophrenia-risk allele (T) at p.(Ala391Thr) would be associated with

a more severe clinical presentation, poorer cognitive ability and educational attainment, and

86 younger age of onset. We expanded the analysis to test for similar phenotypic associations in

87 a large sample of the general population (UK Biobank unaffected controls). Given that

88 SLC39A8 is also constrained for loss of function and missense variants (Genome Aggregation

89 Database [gnomAD] v2.1.1; 9), we used the UK Biobank to tested for phenotypic

90 associations with rare protein-truncating and deleterious missense variants within *SLC39A8*.

91 Methods

92

This study followed the guidelines outlined in the STrengthening the REporting of Genetic
Association Studies (STREGA) (10), an extension of the STROBE Statement (checklist in
the Supplementary Material).

96

We analysed data from three cohorts recruited at Cardiff University and data from the UK
Biobank. Full details on how samples were ascertained and how phenotypes were measured,

- 99 calculated, and standardised, can be found in the Supplementary Material. A brief overview
- 100 is provided below.
- 101

102 Cardiff Schizophrenia Samples

103

104 Participants

105 Participants were recruited into three cross-sectional studies, all of which have been

106 previously described: CardiffCOGS (11), Cardiff F-series (12) and Cardiff Affected-Sibs (13)

107 samples. The Cardiff Affected-Sibs sample includes a single affected individual from

108 families with two or more siblings diagnosed with schizophrenia or schizoaffective disorder.

109 All participants were recruited from in-patient, voluntary sector, and community mental

110 health services across the UK and underwent a clinical research interview based on the

111 Schedules for Clinical Assessment in Neuropsychiatry (SCAN), with further information

112 available from clinical records. For these analyses, we only retained participants who met

113 DSM-IV or ICD-10 criteria for a diagnosis of schizophrenia or schizoaffective disorder,

114 depressed type.

115

116 Phenotypes

117 The Scale for the Assessment of Positive Symptoms (SAPS) and the Scale for the

118 Assessment of Negative Symptoms (SANS) were scored on a lifetime worst basis using

119 information from the SCAN interview and lifetime psychiatric clinical records. These records

120 were also used to ascertain age at psychosis onset. The Measurement and Treatment Research

121 to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery was used

122 as a measure of current cognitive ability in the CardiffCOGS sample. As described in Legge,

123 Cardno (14), a confirmatory factor analysis (CFA) framework was used to estimate

| 124 | phenotype-derived factor scores from the symptom and cognitive ratings, which we refer to |
|-----|---|
| 125 | as symptom dimensions. Using all three samples, the best model had three symptom |
| 126 | dimensions: positive symptoms (SAPS global hallucinations and SAPS global delusions), |
| 127 | negative symptoms of diminished expressivity (SANS global affective flattening and SANS |
| 128 | global alogia), and disorganised symptoms (SAPS global positive formal thought disorder |
| 129 | and SANS inappropriate affect). As CardiffCOGS was the only sample to have data on |
| 130 | cognitive ability, a second CFA framework, using only this sample, was used to estimate |
| 131 | phenotype-derived factor scores from the MATRICS domain scores as well as the symptom |
| 132 | ratings. The best model had five dimensions: positive symptoms (as above), negative |
| 133 | symptoms of diminished expressivity (as above), disorganised symptoms (as above), negative |
| 134 | symptoms of motivation and pleasure (SANS global anhedonia/asociality and SANS global |
| 135 | avolition/apathy), and cognitive ability (all MATRICS domains apart from social cognition). |
| 136 | |
| 137 | As well as the cognitive domain, which captures current cognitive ability, premorbid IQ was |
| 138 | assessed in the CardiffCOGS sample using the National Adult Reading Test (NART). |
| 139 | Educational attainment was measured across all three samples using years in education and |
| 140 | highest educational qualification (General Certificate of Secondary Education [GCSE]/no |
| 141 | GCSE, note GCSEs are taken by most UK pupils upon the completion of compulsory |
| 142 | education [from 1972-2013 this was at age 16], and degree/no degree). |
| 143 | |
| 144 | Genotypes |
| 145 | Conome wide SND data for the three complex were cureted and hermonized as part of |

145 Genome-wide SNP data for the three samples were curated and harmonised as part of

146 DRAGON-Data (15) (see Supplementary Material). Genotypes for p.(Ala391Thr)

147 (INFO=0.996) were extracted for each participant. Principal components were calculated

148 using pruned SNPs.

149

150 Genetic ancestry probabilities were calculated using Ancestry Informative Markers (AIMs) 151 derived from the Allen Ancient DNA Resource reference panel, linear discriminant analysis 152 (LDA), and biogeographical categories defined by Huddart, Fohner (16). AIMs are genetic 153 variants with highly divergent allele frequencies across biogeographical genetic ancestries, 154 which can capture genetic associations between an individual and a particular 155 (sub)continental population (17). Ancestry groups were determined by assigning individuals 156 to their most probable biogeographical category as inferred by LDA (determined using 157 Youden's index as optimality criterion), with individuals not meeting a probability threshold 158 for any category being assigned to an "admixed" group. The schizophrenia risk allele is 159 thought to have been under recent positive selection in Europeans (18); in Phase 3 of the 160 1000 Genomes Project, the schizophrenia allele is present in around 8% of European samples 161 but is reported to be almost absent from other populations (1). In our data, only Europeans 162 carried two copies of the schizophrenia risk allele. However, to increase our sample size and 163 improve the generalisability of our findings, we restricted our sample to participants from 164 ancestries where the schizophrenia-risk allele was present in at least one individual: African 165 American/Afro-Caribbean (0.48%), Central/South Asian (1.06%), European (98.21%), and 166 Middle Eastern/North African (0.24%) (note the Middle Eastern/North African ancestry is 167 referred to as Near Eastern in Huddart, Fohner (16)).

168

169 UK Biobank

170

171 Participants

Participants were from the UK Biobank (UKBB), a large-scale biomedical database of
individuals aged between 40-69 who were recruited from across the UK (19). Participants

174 underwent extensive phenotyping. All UKBB field IDs used in this study are reported in the

175 Supplementary Material. For these analyses, we removed participants with a psychotic

176 spectrum disorder (ICD-10 F20-F29, see Supplementary Material).

- 177
- 178 Phenotypes

179 An abridged version of the Composite International Diagnostic Interview psychosis module 180 (lifetime version) was used in the online follow-up mental health questionnaire. As in Legge, 181 Jones (5), we derived three overlapping binary variables: (i) any psychotic experience defined 182 as a positive response to any of the four symptom questions; (ii) a distressing psychotic experience, defined as any psychotic experience that was rated as "a bit," "quite," or "very" 183 184 distressing; and (iii) multiple occurrences of psychotic experiences, defined as any psychotic 185 experience that occurred on more than one occasion. The comparator group for these three 186 variables was comprised of individuals who provided a negative response to all four 187 psychotic experience symptom questions (see Supplementary Material). We also looked at 188 delusions of persecution alone (UKBB Field 20468: "Ever believed in an un-real conspiracy 189 against self") as previous work has suggested that this phenotype in the UKBB is particularly 190 enriched for genetic liability for schizophrenia (5).

191

Cognitive ability was measured using a general intelligence factor, g, which is considered a reliable measure of cognitive ability. As in Fawns-Ritchie and Deary (20), g was calculated using principal component analysis (PCA). Four cognitive tests went into the PCA (numeric memory, reaction time, pairs matching, and trail making test (TMT) B, see Supplementary Material) and the first PC was considered an estimate of g. A positive g score represents better cognitive performance. Alongside the g score, the cognitive test of verbal and numerical reasoning, also referred to as the test for fluid intelligence, was used to measure

- 199 current cognitive ability. Educational attainment was measured using years in education (for
- 200 those without a college or university degree) and highest educational qualification
- 201 (GCSEs/no GCSEs and degree/no degree).
- 202
- 203 Genotypes

204 Genotype data were curated by the UKBB (21) and as described in Leonenko, Baker (22) 205 (see Supplementary Material). The genotypes for p.(Ala391Thr) (INFO=1.00) were extracted 206 for each participant. Principal components provided by the UKBB were used. We restricted 207 our sample to participants who self-reported White British or Irish ancestry then used the first 208 five principal components to identify a subsample of participants that was relatively 209 genetically homogenous. As in Legge, Jones (5), we computed a Minimum Covariance 210 Determinant (MCD) estimator of location and scatter for each participant, and used these to 211 define a hyper-ellipsoid in a multi-dimensional space that contains the majority of MCD 212 points. We used this hyper-ellipsoid to include participants within the 90th percentile of the 213 MCD distance (see Figure 9 in the Supplementary Material). 214

215 Rare Variants

216 Full methods of rare variant calls are reported in Fenner, Holmans (23). In brief, exome 217 sequencing data released for 200,619 UKBB participants in October 2020 were used for the 218 current study. Variants were annotated in Hail using Ensembl's VEP. Protein-truncating 219 variants (PTVs) were defined as splice acceptor, splice donor, stop-gain or frameshift 220 variants that were annotated as high confidence for causing loss of protein function by Loss-221 Of-Function Transcript Effect Estimator (LoFTEE; 9). Deleterious missense variants were 222 defined as missense variants with a Rare Exome Variant Ensemble Learner score (REVEL; 24) > 0.75. PTVs and missense variants were grouped together into one 'damaging' category 223

for analysis. Rare variants were defined as those with allele counts ≤ 5 in the sample reported

in Fenner, Holmans (23). We included, as a covariate, the burden of synonymous variants

that had allele counts ≤ 5 in the sample reported in Fenner, Holmans (23).

227

228 Statistical Analysis

229 Each phenotype was regressed onto p.(Ala391Thr) using linear or logistic regression models. 230 Sex, age at interview, the first five genetic principal components (PCs), and any further PCs 231 which were associated with p.(Ala391Thr) (PC 6 and 9 in the Cardiff F-Series sample) were 232 included as covariates. For the UKBB data, the first ten genetic PCs and genotype batch were 233 included as covariates. For models where a measure of cognitive ability in the UKBB was 234 used as the outcome, age at interview squared was also included as a covariate (25), this 235 variable was centred before being transformed to prevent the occurrence of collinearity (26). 236 For the Cardiff schizophrenia samples, missing phenotype data were imputed, for each 237 sample separately, using multiple imputation by chained equations (MICE; 100 imputations, 238 10 iterations in the burn-in period). All regression analyses were run in each of the 100 239 imputed datasets separately and then pooled using Rubin's rules (27). Model assumptions 240 were checked using the R package 'performance' and discussed in the Supplementary 241 Material: for models were there was evidence of multicollinearity (variance inflation factor 242 $[VIF] \ge 10$, we removed PCs from the model until the VIF for p.(Ala391Thr) was < 10, and 243 for models where there was evidence of heteroscedasticity (Breusch-Pagan Test P-value < 244 0.01), we recalculated standard errors, confidence intervals, and P-values using Eicker-245 Huber-White robust "HC2" standard errors. For the Cardiff schizophrenia samples, beta 246 values or log(odds) were meta-analysed, and weighted using their standard errors, using the R 247 package 'metafor' using a fixed-effect inverse-variance weighted model. We corrected for 248 multiple testing of phenotypes in the meta-analysis, and within each sample, using the

- 249 Benjamini–Hochberg False Discovery Rate (FDR) method and used an alpha level of $\leq .05$
- 250 for the adjusted p-values to determine statistical significance. For the rare variant analysis,
- 251 each of the phenotypes was regressed against the number of rare variants, and adjusted for
- the number of rare synonymous variants each person carries in SLC39A8, age at interview
- 253 (age at interview squared for g and FI), sex, exome data PC1-10, and sequencing batch.

254 Results

- 255 Phenotype means and proportions, stratified by p.(Ala391Thr) schizophrenia-risk allele
- count, are presented for each sample in the Supplementary Material.
- 257

258 Cardiff Schizophrenia Samples

- 259 Data were available for 662 participants from CardiffCOGS (mean age at interview
- 260 [AAI]=43.31 years, standard deviation [sd]=12.11; 65.75% male), 422 from Cardiff F-Series
- 261 (mean AAI=42.11 years, sd=14.08; 70.66% male) and 148 from Cardiff SibPairs (mean
- AAI=41.68 years, sd=12.93; 66.21% male).

263

- 264 p.(Ala391Thr) was not associated with positive symptoms, negative symptoms, or
- disorganised symptoms derived in either CFA model (Table 1 and Table 2). p.(Ala391Thr)
- 266 was not associated with current cognitive ability in CardiffCOGS, however, it was nominally
- associated with a lower NART IQ score but this association did not survive correction for
- 268 multiple testing (Table 2). Although I² should be interpreted cautiously in meta-analyses of
- 269 only a few studies (28), there does not appear to be evidence of between-study heterogeneity
- after meta-analysing phenotypes which were present in all three samples.

271

UK Biobank

- 273 Data were available for N=355,069 participants from UKBB who did not have a psychotic
- spectrum disorder (mean AAI=56.92 years, sd=7.96; 46.25% male), of which N=354,509
- indicated that they were willing to attempt the cognitive tests and N=116,935 completed the
- 276 online follow-up mental health questionnaire.

| 278 | p.(Ala391Thr) was not associated with reported psychotic experiences. However, the |
|-----|---|
| 279 | schizophrenia-risk allele was associated with a lower g score ($\beta = -0.05$; 95% CI, -0.07 to - |
| 280 | 0.02; FDR-adjusted p-value=8.61 x 10^{-5}), a lower fluid intelligence score (β =-0.05; 95% CI, - |
| 281 | 0.07 to -0.04; FDR-adjusted p-value=3.35 x 10 ⁻¹⁰), a lower likelihood of obtaining GCSEs |
| 282 | (OR=0.96; 95% CI, 0.94-0.98; FDR-adjusted p-value=6.21 x 10 ⁻⁵) or a degree-level |
| 283 | qualification (OR=0.95; 95% CI, 0.93-0.97; FDR-adjusted p-value=6.03 x10 ⁻⁶) and fewer |
| 284 | years in education (β =-0.03; 95% CI, -0.05 to 0.00; FDR-adjusted p-value=0.035) (Table 3). |
| 285 | |
| 286 | Rare variant calls were available for N=134,370 (37.84%) of the participants included in the |
| 287 | current study. N=46 carried rare synonymous variants and N=13 carried rare damaging |
| 288 | variants (N=6 PTVs and N=7 missense carriers; mean AAI=55.54 years, sd=9.92; 46.15% |
| 289 | male). Most rare variant carriers had missing phenotype data. Rare variants in SLC39A8 were |
| 290 | nominally associated with lower g (N rare variants=2; β = -1.67; 95% CI, -2.93 to -0.42; P- |
| 291 | value=0.009) and lower fluid intelligence (N rare variants=1; β = -2.31; 95% CI, -4.25 to - |
| 292 | 0.38; P-value=0.019) but this association did not survive correction for multiple testing |
| 293 | (Table 4). None of the rare variant carriers had a diagnosis of Intellectual Disability (ICD-10 |
| 294 | Codes F70, F71, F72, F78, or F79 identified from the hospital, death, and primary care |
| 295 | records). |

296 Discussion

297

298 In this study, we found that the schizophrenia-risk allele at p.(Ala391Thr) was associated 299 with poorer cognitive ability, but not psychotic experiences, in a volunteer sample, drawn 300 from the general population, without psychotic spectrum disorders. The schizophrenia-risk 301 allele was also nominally associated with lower premorbid IO in patients with schizophrenia; 302 larger independent samples are required to confirm this result. Exploratory analysis of rare 303 variants in *SLC39A8*, in our subsample of the UKBB, suggested that rare variants are 304 nominally associated with poorer cognition but was not decisive due to the low number of 305 rare variant carriers with phenotype data. 306 307 Although understanding the potential pathophysiological mechanisms of variants identified 308 by GWAS is challenging, there is an increasing focus on p.(Ala391Thr) in the context of the 309 aetiology of schizophrenia (1) and some proposed mechanisms are also thought to play a role 310 in cognition, p.(Ala391Thr) is thought to lead to synaptic glutamate receptor hypofunction, in 311 part, because of downregulated surface localisation of GluA1, GluA2/3, GluN1, and GluN2A 312 (3). The latter are subunits of the N-methyl-d-aspartate (NMDA) receptor and the 313 hypofunctioning of NMDAR has been implicated in the aetiology schizophrenia and 314 specifically impaired learning and memory (29). The schizophrenia-risk allele at 315 p.(Ala391Thr) has also been associated with lower manganese levels (2, 30, 31), an essential 316 trace element transported by ZIP8 and involved in glycosylation, the process by which 317 branched sugar polymers are covalently attached to proteins and lipids (32). Glycosylation is 318 dysregulated in schizophrenia (32) and disrupted by the schizophrenia-risk allele at 319 p.(Ala391Thr) (33). Individuals with Congenital Disorders of Glycosylation can present with 320 cognitive impairment (32), but there is no consistent linear association between lower blood

321 manganese concentrations and poorer cognitive ability (34). Finally, the schizophrenia-risk 322 allele is also associated with impaired zinc uptake and transportation, and decreased cortical 323 dendritic spine density (35). Developmental synaptic pruning has been postulated as a risk 324 mechanism for schizophrenia either through a loss of balance between synaptogenesis and 325 elimination or abnormal activity-dependent plasticity (36). Decreased dendritic spine density 326 has been observed in individuals with schizophrenia (37). Dendritic spine plasticity is thought 327 to underlie the cognitive resilience of older adults who, despite having Alzheimer's 328 pathophysiology, have not developed dementia (38).

329

330 p.(Ala391Thr) has been reported to be a highly pleiotropic variant and is associated, at 331 genome-wide significance levels, with 24.16% (129/534) of the traits curated by Open 332 Targets Genetics (39); the schizophrenia-risk allele has been associated with lower HDL 333 cholesterol, lower blood pressure, lower levels of apolipoprotein A1, calcium, aspartate 334 aminotransferase, urate, gamma-glutamyl transferase, and serum albumin, as well as higher 335 body mass index and body fat measures, but a lower risk of hypertension and cardiovascular 336 disease. Notably, in GWAS, other than in schizophrenia, p.(Ala391Thr) has not been 337 associated with any psychiatric disorder (Bipolar Disorder, Major Depressive Disorder) or 338 with neurodevelopmental (Autism, Attention deficit hyperactivity disorder), or 339 neurodegenerative (Alzheimer's Disease, Parkinson's Disease) disorders (see Buniello, 340 MacArthur (40) and Supplementary Table 1). In phenome-wide association studies 341 (PheWAS) using the UK Biobank (UKBB), p.(Ala391Thr) has been associated with diseases 342 of the oesophagus, musculoskeletal conditions, metabolic and digestive biomarkers, blood 343 pressure, and dietary and lifestyle factors including weight gain and drinking alcohol (30, 344 http://www.nealelab.is/uk-biobank/, 41). In a brain MRI PheWAS of the UKBB (42), the 345 schizophrenia risk allele was associated with greater putamen grey matter volume, reduced

cortical thickness, and reduced white matter integrity, MRI phenotypes which have been
identified in participants with schizophrenia. Although pleiotropy has benefits for
translational research, for example by cutting across current diagnostic categories, the
diversity of phenotypes suggests that *SLC39A8* may not impact schizophrenia or cognition
through the disruption of a single key biological process, rather it may influence multiple
processes, not necessarily all within the brain.

352

353 As well as increasing our understanding of the aetiology of schizophrenia, studying

354 p.(Ala391Thr) could improve our understanding of the cognitive impairments in people with

355 schizophrenia. Within studies of cognitive remediation therapy (CRT) in schizophrenia,

although on average patients with poorer premorbid IQ and fewer years in education show

357 greater improvement after CRT, some studies have shown the opposite (43) and there is

358 emerging literature examining whether genetic variants can account for this differential

359 improvement (44). For example, one study examined *SLC1A2*, a high-affinity glutamate

360 transporter that encodes EAAT2, and found that the minor allele at

361 NC_000011.10:g.35419429T>G (rs4354668), which has previously been associated with

362 lower EAAT2 expression and poorer cognition in healthy controls and patients with

363 schizophrenia, was associated with poorer improvement after CRT (45). p.(Ala391Thr) could

364 be a candidate for future stratification studies.

365

366 Limitations

367

368 This is the first study to test the relationship between p.(Ala391Thr) and schizophrenia-

369 related phenotypes in participants with the disorder. However, our cohorts of schizophrenia

370 participants were small, and it may be that larger sample sizes are needed to detect the small

371 effects attributable to a single SNP. Given an alpha level of 0.05, and 90% power, to observe 372 a beta coefficient between -0.07 to -0.02, between N=1741 and N=21403 schizophrenia 373 participants would be required. Our analysis of rare variants in SLC39A8 may not be 374 representative because of the small number of rare variant carriers driving the associations. 375 Gene-based burden tests usually apply a cut off to exclude genes with a low a number of 376 carriers (46), which, in our sample, would have excluded SLC39A8 from a pipeline for 377 exome-wide gene-based burden tests. Our rare variant results should therefore be used to 378 inform future studies rather than be interpreted in isolation. It is also possible that our 379 findings will not generalise to participants of non-European ancestry. Previously work has 380 described p.(Ala391Thr) as having an almost negligible minor allele frequency in non-381 European populations (1). In our schizophrenia cohorts, only Europeans carried two copies of 382 the schizophrenia risk allele but three other ancestry groups (African American/Afro-383 Caribbean, Near Eastern, and Central/South Asian) contained participants with one copy so 384 we chose to include them in our analysis. Nevertheless, less than 2% of the schizophrenia 385 cohorts were of non-European ancestry and our sample from the UKBB was comprised 386 solely of people with European ancestry.

387

388 Another caveat is that it is unclear whether psychotic experiences measured in the UKBB are 389 a good proxy for psychotic experiences experienced by people with schizophrenia. Although 390 there is a shared genetic liability between psychotic experiences and schizophrenia, the 391 genetic correlation is weak (rg = 0.21; 5), and psychotic experiences were more strongly 392 correlated with ADHD (rg = 0.24), autism spectrum disorder (rg = 0.39), and major 393 depressive disorder (rg=0.46) than schizophrenia, suggesting that these phenotypes capture 394 general psychopathology rather than schizophrenia-specific psychosis. There is also the 395 possibility of measurement error in the psychotic experiences phenotypes; firstly, because

396 they are measured retrospectively by self-report, and, secondly, because of biases in those 397 who attempt to complete the online follow-up mental health questionnaire. Legge, Jones (5) 398 found that participants who completed the mental health questionnaire had significantly 399 higher intelligence and lower schizophrenia polygenic risk scores adding to existing evidence 400 of a "healthy volunteer" selection bias in the UKBB (47, 48) which can affect the results of 401 GWAS (49). As the schizophrenia-risk allele was associated with responding to questions in 402 the UKBB with 'prefer not to answer' and 'I don't know' (50), we tested whether 403 p.(Ala391Thr) was associated with willingness to attempt the cognitive tests or the mental 404 health questionnaire. p.(Ala391Thr) was not associated with attempting to complete the 405 baseline cognitive tests, but the schizophrenia-risk allele was associated with *not* attempting 406 the mental health questionnaire (see Supplementary Material). This suggests that the 407 psychotic experiences phenotypes in the UKBB are not completed by participants with a 408 higher genetic load for schizophrenia and our analyses may be affected by collider bias. 409

410 Conclusions

411

The schizophrenia-risk allele at p.(Ala391Thr) is associated with poorer cognitive ability in a sample of the general population with European ancestry. Larger and more ancestrallydiverse studies of participants with schizophrenia are required to determine whether there is an association between p.(Ala391Thr) and cognition in schizophrenia, and subsequently determine whether p.(Ala391Thr) and ZIP8 are potential targets for novel therapeutic treatments for cognitive impairment in those with the disorder.

419 Data Availability

- 420 To comply with the ethical and regulatory framework under which the Cardiff Schizophrenia
- 421 Samples were obtained, access to individual-level data requires a collaboration agreement
- 422 with Cardiff University; requests to access these datasets should be directed to J.T.R.W.
- 423 (WaltersJT@cardiff.ac.uk) and M.J.O. (OwenMJ@cardiff.ac.uk). UK Biobank data is
- 424 available by application to the UK Biobank (<u>www.ukbiobank.ac.uk</u>).
- 425 Code Availability
- 426 <u>https://zenodo.org/records/10027873</u>

medRxiv preprint doi: https://doi.org/10.1101/2024.09.18.24313865; this version posted September 19, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

perpetuity. It is made available under a CC-BY-ND 4.0 International license .

427 References

428

429

430 Costas J. The highly pleiotropic gene SLC39A8 as an opportunity to gain insight into 1. 431 the molecular pathogenesis of schizophrenia. Am J Med Genet B Neuropsychiatr Genet. 432 2018;177(2):274-83. 433 Fujishiro H, Miyamoto S, Sumi D, Kambe T, Himeno S. Effects of individual amino acid 2. mutations of zinc transporter ZIP8 on manganese- and cadmium-transporting activity. 434 435 Biochemical and Biophysical Research Communications. 2022;616:26-32. 436 Tseng WC, Reinhart V, Lanz TA, Weber ML, Pang J, Le KXV, et al. Schizophrenia-3. 437 associated SLC39A8 polymorphism is a loss-of-function allele altering glutamate receptor 438 and innate immune signaling. Transl Psychiatry. 2021;11(1):136. 439 Trubetskoy V, Pardiñas AF, Qi T, Panagiotaropoulou G, Awasthi S, Bigdeli TB, et al. 4. 440 Mapping genomic loci implicates genes and synaptic biology in schizophrenia. Nature. 2022. 441 Legge SE, Jones HJ, Kendall KM, Pardiñas AF, Menzies G, Bracher-Smith M, et al. 5. 442 Association of Genetic Liability to Psychotic Experiences With Neuropsychotic Disorders and 443 Traits. JAMA Psychiatry. 2019;76(12):1256-65. 444 Savage JE, Jansen PR, Stringer S, Watanabe K, Bryois J, de Leeuw CA, et al. Genome-6. 445 wide association meta-analysis in 269,867 individuals identifies new genetic and functional 446 links to intelligence. Nature Genetics. 2018;50(7):912-9. 447 7. Okbay A, Wu Y, Wang N, Jayashankar H, Bennett M, Nehzati SM, et al. Polygenic 448 prediction of educational attainment within and between families from genome-wide 449 association analyses in 3 million individuals. Nat Genet. 2022;54(4):437-49. 450 Demange PA, Malanchini M, Mallard TT, Biroli P, Cox SR, Grotzinger AD, et al. 8. 451 Investigating the genetic architecture of noncognitive skills using GWAS-by-subtraction. 452 Nature Genetics. 2021;53(1):35-44. 453 9. Karczewski KJ, Francioli LC, Tiao G, Cummings BB, Alföldi J, Wang Q, et al. The 454 mutational constraint spectrum quantified from variation in 141,456 humans. Nature. 455 2020;581(7809):434-43. 456 Little J, Higgins JPT, Ioannidis JPA, Moher D, Gagnon F, von Elm E, et al. 10. 457 STrengthening the REporting of Genetic Association Studies (STREGA)—an extension of the 458 STROBE statement. Genetic Epidemiology. 2009;33(7):581-98. 459 Legge SE, Dennison CA, Pardiñas AF, Rees E, Lynham AJ, Hopkins L, et al. Clinical 11. 460 indicators of treatment-resistant psychosis. The British Journal of Psychiatry. 461 2020;216(5):259-66. 462 12. Williams NM, Green EK, Macgregor S, Dwyer S, Norton N, Williams H, et al. Variation 463 at the DAOA/G30 locus influences susceptibility to major mood episodes but not psychosis 464 in schizophrenia and bipolar disorder. Arch Gen Psychiatry. 2006;63(4):366-73. 465 Williams NM, Rees MI, Holmans P, Norton N, Cardno AG, Jones LA, et al. A Two-13. 466 Stage Genome Scan for Schizophrenia Susceptibility Genes in 196 Affected Sibling Pairs. 467 Human Molecular Genetics. 1999;8(9):1729-39. 468 14. Legge SE, Cardno AG, Allardyce J, Dennison C, Hubbard L, Pardiñas AF, et al. 469 Associations Between Schizophrenia Polygenic Liability, Symptom Dimensions, and 470 Cognitive Ability in Schizophrenia. JAMA Psychiatry. 2021;78(10):1143-51.

medRxiv preprint doi: https://doi.org/10.1101/2024.09.18.24313865; this version posted September 19, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY-ND 4.0 International license .

471 15. Lynham AJ, Knott S, Underwood JFG, Hubbard L, Agha SS, Bisson JI, et al. DRAGON-472 Data: a platform and protocol for integrating genomic and phenotypic data across large 473 psychiatric cohorts. BJPsych Open. 2023;9(2):e32. 474 Huddart R, Fohner AE, Whirl-Carrillo M, Wojcik GL, Gignoux CR, Popejoy AB, et al. 16. 475 Standardized Biogeographic Grouping System for Annotating Populations in 476 Pharmacogenetic Research. Clinical Pharmacology & Therapeutics. 2019;105(5):1256-62. 477 17. Bulbul O, Filoglu G, Zorlu T, Altuncul H, Freire-Aradas A, Söchtig J, et al. Inference of 478 biogeographical ancestry across central regions of Eurasia. International journal of legal 479 medicine. 2016;130(1):73-9. 480 18. Li M, Wu DD, Yao YG, Huo YX, Liu JW, Su B, et al. Recent Positive Selection Drives the 481 Expansion of a Schizophrenia Risk Nonsynonymous Variant at SLC39A8 in Europeans. 482 Schizophr Bull. 2016;42(1):178-90. 483 Sudlow C, Gallacher J, Allen N, Beral V, Burton P, Danesh J, et al. UK Biobank: An 19. 484 Open Access Resource for Identifying the Causes of a Wide Range of Complex Diseases of 485 Middle and Old Age. PLOS Medicine. 2015;12(3):e1001779. 486 20. Fawns-Ritchie C, Deary IJ. Reliability and validity of the UK Biobank cognitive tests. 487 PLOS ONE. 2020;15(4):e0231627. 488 Bycroft C, Freeman C, Petkova D, Band G, Elliott LT, Sharp K, et al. The UK Biobank 21. 489 resource with deep phenotyping and genomic data. Nature. 2018;562(7726):203-9. 490 Leonenko G, Baker E, Stevenson-Hoare J, Sierksma A, Fiers M, Williams J, et al. 22. 491 Identifying individuals with high risk of Alzheimer's disease using polygenic risk scores. 492 Nature Communications. 2021;12(1):4506. 493 Fenner E, Holmans P, O'Donovan MC, Owen MJ, Walters JT, Rees E. Rare coding 23. 494 variants in schizophrenia-associated genes affect generalised cognition in the UK Biobank. 495 medRxiv. 2023:2023.08. 14.23294074. 496 24. Ioannidis NM, Rothstein JH, Pejaver V, Middha S, McDonnell SK, Baheti S, et al. 497 REVEL: an ensemble method for predicting the pathogenicity of rare missense variants. The 498 American Journal of Human Genetics. 2016;99(4):877-85. 499 25. Cornelis MC, Wang Y, Holland T, Agarwal P, Weintraub S, Morris MC. Age and 500 cognitive decline in the UK Biobank. PLOS ONE. 2019;14(3):e0213948. 501 Schielzeth H. Simple means to improve the interpretability of regression coefficients. 26. 502 Methods in Ecology and Evolution. 2010;1(2):103-13. 503 Rubin DB. Multiple imputation for nonresponse in surveys: John Wiley & Sons; 2004. 27. 504 von Hippel PT. The heterogeneity statistic I2 can be biased in small meta-analyses. 28. 505 BMC Medical Research Methodology. 2015;15(1):35. 506 29. Nakazawa K, Sapkota K. The origin of NMDA receptor hypofunction in schizophrenia. 507 Pharmacology & Therapeutics. 2020;205:107426. Moksnes MR, Hansen AF, Wolford BN, Thomas LF, Rasheed H, Simić A, et al. New 508 30. 509 insights into the genetic etiology of 57 essential and non-essential trace elements in 510 humans. medRxiv. 2023:2023.04.25.23289097. 511 31. Mealer RG, Jenkins BG, Chen CY, Daly MJ, Ge T, Lehoux S, et al. The schizophrenia 512 risk locus in SLC39A8 alters brain metal transport and plasma glycosylation. Scientific 513 Reports. 2020;10(1):13162. 514 Pradeep P, Kang H, Lee B. Glycosylation and behavioral symptoms in neurological 32. 515 disorders. Translational Psychiatry. 2023;13(1):154.

medRxiv preprint doi: https://doi.org/10.1101/2024.09.18.24313865; this version posted September 19, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY-ND 4.0 International license .

516 33. Mealer RG, Williams SE, Noel M, Yang B, D'Souza AK, Nakata T, et al. The 517 schizophrenia-associated variant in SLC39A8 alters protein glycosylation in the mouse brain. 518 Molecular Psychiatry. 2022;27(3):1405-15. 519 34. Vollet K, Haynes EN, Dietrich KN. Manganese Exposure and Cognition Across the 520 Lifespan: Contemporary Review and Argument for Biphasic Dose–Response Health Effects. 521 Current Environmental Health Reports. 2016;3(4):392-404. 522 Li S, Ma C, Li Y, Chen R, Liu Y, Wan LP, et al. The schizophrenia-associated missense 35. 523 variant rs13107325 regulates dendritic spine density. Translational Psychiatry. 524 2022;12(1):361. 525 36. Kasai H, Fukuda M, Watanabe S, Hayashi-Takagi A, Noguchi J. Structural dynamics of 526 dendritic spines in memory and cognition. Trends in Neurosciences. 2010;33(3):121-9. 527 Radhakrishnan R, Skosnik PD, Ranganathan M, Naganawa M, Toyonaga T, Finnema S, 37. 528 et al. In vivo evidence of lower synaptic vesicle density in schizophrenia. Molecular 529 Psychiatry. 2021;26(12):7690-8. 530 38. Boros BD, Greathouse KM, Gentry EG, Curtis KA, Birchall EL, Gearing M, et al. 531 Dendritic spines provide cognitive resilience against Alzheimer's disease. Annals of 532 Neurology. 2017;82(4):602-14. 533 39. Mountjoy E, Schmidt EM, Carmona M, Schwartzentruber J, Peat G, Miranda A, et al. 534 An open approach to systematically prioritize causal variants and genes at all published 535 human GWAS trait-associated loci. Nat Genet. 2021;53(11):1527-33. 536 40. Buniello A, MacArthur JAL, Cerezo M, Harris LW, Hayhurst J, Malangone C, et al. The 537 NHGRI-EBI GWAS Catalog of published genome-wide association studies, targeted arrays 538 and summary statistics 2019. Nucleic acids research. 2019;47(D1):D1005-D12. 539 MRC IEU UK Biobank GWAS pipeline version 2 [Internet]. 2019. 41. 540 42. Hermann ER, Chambers E, Davis DN, Montgomery MR, Lin D, Chowanadisai W. Brain 541 Magnetic Resonance Imaging Phenome-Wide Association Study With Metal Transporter 542 Gene SLC39A8. Front Genet. 2021;12:647946. 543 43. Vita A, Barlati S, Ceraso A, Nibbio G, Ariu C, Deste G, et al. Effectiveness, Core 544 Elements, and Moderators of Response of Cognitive Remediation for Schizophrenia: A 545 Systematic Review and Meta-analysis of Randomized Clinical Trials. JAMA Psychiatry. 546 2021;78(8):848-58. 547 44. Penadés R, Bosia M, Catalán R, Spangaro M, García-Rizo C, Amoretti S, et al. The role 548 of genetics in cognitive remediation in schizophrenia: A systematic review. Schizophr Res 549 Cogn. 2020;19:100146. 550 Spangaro M, Bosia M, Bechi M, Buonocore M, Cocchi F, Guglielmino C, et al. 45. 551 Neurobiology of cognitive remediation in schizophrenia: Effects of EAAT2 polymorphism. 552 Schizophrenia Research. 2018;202:106-10. Chen C-Y, Tian R, Ge T, Lam M, Sanchez-Andrade G, Singh T, et al. The impact of rare 553 46. 554 protein coding genetic variation on adult cognitive function. Nature Genetics. 555 2023;55(6):927-38. 556 Fry A, Littlejohns TJ, Sudlow C, Doherty N, Adamska L, Sprosen T, et al. Comparison 47. 557 of Sociodemographic and Health-Related Characteristics of UK Biobank Participants With 558 Those of the General Population. Am J Epidemiol. 2017;186(9):1026-34. 559 Legge SE, Pardiñas AF, Woolway G, Rees E, Cardno AG, Escott-Price V, et al. An 48. 560 Assessment of the Genetic and Phenotypic Features of Schizophrenia in the UK Biobank 561 JAMA Psychiatry. Under Review.

- 562 49. Schoeler T, Speed D, Porcu E, Pirastu N, Pingault J-B, Kutalik Z. Participation bias in
- 563 the UK Biobank distorts genetic associations and downstream analyses. Nature Human 564 Behaviour. 2023;7(7):1216-27.
- 565 Mignogna G, Carey CE, Wedow R, Baya N, Cordioli M, Pirastu N, et al. Patterns of 50.
- 566 item nonresponse behaviour to survey questionnaires are systematic and associated with
- 567 genetic loci. Nature Human Behaviour. 2023.

568 Acknowledgements

- 569 We acknowledge the support of the Supercomputing Wales project, which is part-funded by
- 570 the European Regional Development Fund (ERDF) via Welsh Government.

571 Funding

- 572 This study was funded by a grant from Takeda Pharmaceuticals Ltd. to Cardiff University.
- 573 Takeda Pharmaceuticals Ltd. was not involved in the design of the study or the interpretation
- of the results. S.E.L was supported by a grant from NIMH (Award R01MH124873) and a
- 575 Medical Research Council Centre programme grant MR/P005748/1. E.F. was supported by a
- 576 Wellcome Trust Integrative Neuroscience PhD Studentship (108891/B/15/Z/WT). A.F.P. was
- 577 supported by the Academy of Medical Sciences Springboard award (SBF005\1083). S.E.S.,
- 578 A.F.P., M.C.O. and J.T.R.W. are also supported by funding from the European Union's
- 579 Horizon 2020 research and innovation programme under grant agreement No 964874.

580 Author Contributions

- 581 S.E.S. designed and conducted the analysis and drafted the manuscript. S.E.L. conducted the
- 582 confirmatory factor analysis. E.F. called the rare variants. A.F.P. conducted the genetic
- 583 ancestry analysis. A.J.L. scored the MATRICS Consensus Cognitive Battery. V.E-P., E.F.,
- J.H., P.H., S.E.L., M.C.O., M.J.O., A.F.P., G.W., L.W., and J.T.R.W. helped design the
- analysis and interpret the results. All authors revised and approved the final manuscript.

586 Ethical Approval

- 587 CardiffCOGS was approved by the South East Wales Research Ethics Committee Panel
- 588 (reference number: 07/WSE03/110) and received HRA approval. All participants provided
- 589 written informed consent. Multicentre and Local Research Ethics Committee approval was

| 590 | obtained for Cardiff F-Series, and all participants gave written informed consent to |
|-----|--|
| 591 | participate. For Cardiff SibPairs written consent was obtained following local ethical |
| 592 | approval guidelines. Ethical approval for the curation and development of DRAGON-Data |
| 593 | was obtained from Cardiff University's School of Medicine Research Ethics Committee (Ref: |
| 594 | 19/72). We also used data from the UK Biobank (https://www.ukbiobank.ac.uk), the |
| 595 | scientific protocol of which has been reviewed and approved by the North West Multi-centre |
| 596 | Ethics Committee. Our access to the UK Biobank data was under the project number 13310. |
| 597 | Competing Interests |
| 598 | J.H., M.C.O., M.J.O., L.W., and J.T.R.W. were investigators on the grant from Takeda |

- 599 Pharmaceuticals Ltd. to Cardiff University. S.E.S. and G.W. were employed on this grant.
- 600 J.H. is the Chief Medical Officer for MeOmics Precision Medicine Ltd. and M.J.O is the
- 601 recipient of a grant from Akrivia Health, but neither of these companies were involved in this

602 study.